Estimation of an evidence-based benchmark for the optimal endocrine therapy utilization rate in breast cancer

Breast

Volumn 19, Issue 5, 2010, Pages 345-349

  Fong, Andrew ^a   Ng, Weng ^a   Barton, Michael B ^a   Delaney, Geoff P ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Breast cancer; Cancer; Endocrine therapy; Evidence based medicine; Treatment

Indexed keywords

ARTICLE; AUSTRALIA; BREAST CANCER; CANCER INCIDENCE; EVIDENCE BASED MEDICINE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE UTILIZATION; HORMONAL THERAPY; HUMAN; ITALY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT INDICATION; UNITED KINGDOM; UNITED STATES;

EID: 77957137753     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.02.006     Document Type: Article

References (37)

1. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer. Lancet 1998, 351(9114):1451-1467. Trialists' Collaborative Group.
2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717.
3. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9(1):45-53.
4. Harlan L.C., Clegg L.X., Abrams J., Stevens J.L., Ballard-Barbash R. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. J Clin Oncol 2006, 24(6):872-877.
5. Mariotto A.B., Feuer E.J., Harlan L.C., Abrams J. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. J Natl Cancer Inst Monogr 2006, (36):7-15.
6. Mariotto A., Feuer E.J., Harlan L.C., Wun L.M., Johnson K.A., Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst 2002, 94(21):1626-1634.
7. Shen Y., Dong W., Feig B.W., Ravdin P., Theriault R.L., Giordano S.H. Patterns of treatment for early stage breast cancers at the M.D. Anderson Cancer Center from 1997 to 2004. Cancer 2009, 115(10):2041-2051.
8. National Breast Cancer Centre Clinical practice guidelines for the management of early breast cancer 2001, National Health and Medical Research Council, Canberra. 2nd ed.
9. National Breast Cancer Centre Clinical practice guidelines for the management of advanced breast cancer 2001, National Health and Medical Research Council, Canberra. 1st ed.
10. National Breast Cancer Centre Clinical practice guidelines for the management and support of younger women with breast cancer 2004, National Health and Medical Research Council, Canberra. 1st ed.
11. National practice guidelines in oncology - breast cancer 2008, National Comprehensive Cancer Network.
12. British Columbian Agency Cancer management guidelines: breast cancer 2009 Available from:. http://www.bccancer.bc.ca.
13. National Collaborating Centre for Cancer Early and locally advanced breast cancer: diagnosis and treatment 2009, National Institute for Health and Clinical Excellence, Cardiff.
14. Goldhirsch A., Ingle J.N., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20(8):1319-1329.
15. National Cancer Institute Breast cancer treatment (PDQ) [cited 2009 1 November]; Available from:. http://www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional.
16. Guide to the development, implementation and evaluation of clinical practice guidelines 1998, National Health and Medical Research Council.
17. Ponzone R., Montemurro F., Maggiorotto F., Robba C., Gregori D., Jacomuzzi M.E., et al. Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. Ann Oncol 2006, 17(11):1631-1636.
18. Stendahl M., Ryden L., Nordenskjold B., Jonsson P.E., Landberg G., Jirstrom K. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 2006, 12(15):4614-4618.
19. Dowsett M., Allred C., Knox J., Quinn E., Salter J., Wale C., et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008, 26(7):1059-1065.
20. Dowsett M., Houghton J., Iden C., Salter J., Farndon J., A'Hern R., et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006, 17(5):818-826.
21. Centre for Epidemiology and Research 2005 report on adult health from the New South Wales population health Survey 2006, NSW Department of Health, Sydney.
22. Australian Institute of Health and Welfare & Australian Association of Cancer Registries Cancer in Australia 2003 2007, Australian Institute of Health and Welfare, Canberra.
23. Australian Institue of health and Welfare and National breast cancer Centre breast cancer survival by size and nodal status in Australia 2007, Australian Institute of Health and Welfare, Canberra.
24. National Cancer Database Benchmark Reports. Treatment of breast cancer diagnosed in 2006: NCDB, CoC, ACoS; 2006.
25. Northern Yorkshire Cancer Registry Information Service Cancer in the 21st Century 2007, Northern Yorkshire Cancer Registry and Information Service.
26. Roila F., Ballatori E., Patoia L., Palazzo S., Veronesi A., Frassoldati A., et al. Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy. Ann Oncol 2003, 14(6):843-848.
27. Foroudi F., Tyldesley S., Walker H., Mackillop W.J. An evidence-based estimate of appropriate radiotherapy utilization rate for breast cancer. Int J Radiat Oncol Biol Phys 2002, 53(5):1240-1253.
28. Delaney G., Shafiq J., Chappell G., Barton M. Establishing treatment benchmarks for mammography-screened breast cancer population based on a review of evidence-based clinical guidelines. Cancer 2008, 112(9):1912-1922.
29. Bardou V.J., Arpino G., Elledge R.M., Osborne C.K., Clark G.M. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003, 21(10):1973-1979.
30. Colditz G.A., Rosner B.A., Chen W.Y., Holmes M.D., Hankinson S.E. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004, 96(3):218-228.
31. Bernoux A., de Cremoux P., Laine-Bidron C., Martin E.C., Asselain B., Magdelenat H. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Breast Cancer Res Treat 1998, 49(3):219-225. Institut Curie Breast Cancer Study Group.
32. De Maeyer L., Van Limbergen E., De Nys K., Moerman P., Pochet N., Hendrickx W., et al. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?. J Clin Oncol 2008, 26(2):335-336. author reply 6-8.
33. Australian Institute of Health and Welfare & the Australian Association of Cancer Registries Cancer in Australia: an overview 2008, Australian Institute of Health and Welfare, Canberra.
34. National Breast and Ovarian Cancer Centre National breast and ovarian cancer Centre and Royal Australasian College of surgeons National breast cancer audit 2009, National Breast and Ovarian Cancer Centre, Surry Hills, NSW.
35. Australian Institute of Health and Welfare & National Breast Cancer Centre Breast cancer in Australia: an overview 2006, Australian Institute of Health and Welfare, Canberra.
36. Australian Institute of Health and Welfare & National Breast and Ovarian Cancer Centre 2009 Breast cancer in Australia: an overview 2009, AIHW, Canberra, 2009 Contract No.: Cat. no. CAN 46.
37. Chia S.K., Speers C.H., Bryce C.J., Hayes M.M., Olivotto I.A. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004, 22(9):1630-1637.